Walid Kamoun, Vice President and Global Head of Reasearch and Development Oncology at Servier, shared on LinkedIn:
“In all the innovative ADC approaches, this paper might reflect a next-next generation approach.
Simó et al., in Nature, presents an In Vivo antibody ADC click technology. The design is bioorthogonal chemistry. A therapeutic antibody is conjugated with trans-cyclooctene, an ADC with tetrazine. The two are given sequentially and ligate in vivo after systemic delivery, forming a functional antibody-ADC click construct at the tumour.
A highly innovative way to engineer bispecific antibodies, or bispecific ADCs, in vivo. Clinical translation is likely complex. Sequential dosing schedules, ligation efficiency in human tumours and the regulatory path for a two-component product are all non-trivial. It might still open some interesting avenues.
Thanks to Simó et al. for this highly innovative approach.”
Title: Modular in vivo antibody-ADC click to reverse drug resistance in tumours
Authors: Cristina Simó, Alexander C. Vanover, Ricardo D’Oliveira Albanus, Sandeep Surendra Panikar, Shayla Shmuel, Alex Benton, Jader Giraldo-Guzman, José M. Luna, Yifei Xu, Na-Keysha Berry, Nai Keltee, Jingxia Liu, Farrokh Dehdashti, Patrícia M. R. Pereira
Read The Full Article
Other articles featuring Walid Kamoun on OncoDaily.